LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article: [No title information]

Huber, Priscilla / Huc, Marius / Jeansoulin, Lilian / Osnim Kota-Mamah, Aurélie / Melro Costa, Marcia / Guenat, Léa J / Carnesecchi, Stéphanie / Vacher, Gaëlle

Revue medicale suisse

2023 Volume 19, Issue 837, Page(s) 1476–1477

Title translation	Sommeil éclairé : un cauchemar pour le cœur et le métabolisme.
MeSH term(s)	Humans ; Dreams ; Sleep ; Heart ; Thorax
Language	French
Publishing date	2023-08-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2177010-4
ISSN	1660-9379
ISSN	1660-9379
DOI	10.53738/REVMED.2023.19.837.1476
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5998: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: [No title information]

Moudarres, Lana / Najand, Gaëlle / Roch, Laura / Schwitzguebel, Valérie M / Seddiki, Wissem / Soulié, Paola / Vacher, Gaëlle / Carnesecchi, Stéphanie

Revue medicale suisse

2022 Volume 18, Issue 798, Page(s) 1880–1881

Title translation	Testostérone: une générosité sous contrôle.
MeSH term(s)	Humans ; Testosterone
Chemical Substances	Testosterone (3XMK78S47O)
Language	French
Publishing date	2022-10-06
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2177010-4
ISSN	1660-9379
ISSN	1660-9379
DOI	10.53738/REVMED.2022.18.798.1880
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5998: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy.

Locatelli, Manon / Delhaes, Flavien / Cherpin, Ophélie / Black, Margaret E / Carnesecchi, Stéphanie / Preynat-Seauve, Olivier / Hibaoui, Youssef / Krause, Karl-Heinz

Cells

2022 Volume 11, Issue 3

Abstract: Cell therapies based on pluripotent stem cells (PSC), have opened new therapeutic strategies for neurodegenerative diseases. However, insufficiently differentiated PSC can lead to tumor formation. Ideally, safety switch therapies should selectively kill ... ...

Abstract	Cell therapies based on pluripotent stem cells (PSC), have opened new therapeutic strategies for neurodegenerative diseases. However, insufficiently differentiated PSC can lead to tumor formation. Ideally, safety switch therapies should selectively kill proliferative transplant cells while preserving post-mitotic neurons. In this study, we evaluated the potential of nucleoside analogs and thymidine kinase-based suicide genes. Among tested thymidine kinase variants, the humanized SR39 (SR39h) variant rendered cells most sensitive to suicide induction. Unexpectedly, post-mitotic neurons with ubiquitous SR39h expression were killed by ganciclovir, but were spared when SR39h was expressed under the control of the cell cycle-dependent Ki67 promoter. The efficacy of six different nucleoside analogs to induce cell death was then evaluated. Penciclovir (PCV) showed the most interesting properties with an efficiency comparable to ganciclovir (GCV), but low toxicity. We tested three nucleoside analogs in vivo: at concentrations of 40 mg/kg/day, PCV and GCV prevented tumor formation, while acyclovir (ACV) did not. In summary, SR39h under the control of a cell cycle-dependent promoter appears most efficient and selective as safety switch for neural transplants. In this setting, PCV and GCV are efficient inducers of cell death. Because of its low toxicity, PCV might become a preferred alternative to GCV.
MeSH term(s)	Cell- and Tissue-Based Therapy ; Ganciclovir/pharmacology ; Humans ; Neurons/metabolism ; Nucleosides ; Thymidine Kinase/genetics ; Thymidine Kinase/metabolism
Chemical Substances	Nucleosides ; Thymidine Kinase (EC 2.7.1.21) ; Ganciclovir (P9G3CKZ4P5)
Language	English
Publishing date	2022-01-31
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells11030502
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy

Manon Locatelli / Flavien Delhaes / Ophélie Cherpin / Margaret E. Black / Stéphanie Carnesecchi / Olivier Preynat-Seauve / Youssef Hibaoui / Karl-Heinz Krause

Cells, Vol 11, Iss 502, p

2022 Volume 502

Abstract	Cell therapies based on pluripotent stem cells (PSC), have opened new therapeutic strategies for neurodegenerative diseases. However, insufficiently differentiated PSC can lead to tumor formation. Ideally, safety switch therapies should selectively kill proliferative transplant cells while preserving post-mitotic neurons. In this study, we evaluated the potential of nucleoside analogs and thymidine kinase-based suicide genes. Among tested thymidine kinase variants, the humanized SR39 (SR39h) variant rendered cells most sensitive to suicide induction. Unexpectedly, post-mitotic neurons with ubiquitous SR39h expression were killed by ganciclovir, but were spared when SR39h was expressed under the control of the cell cycle-dependent Ki67 promoter. The efficacy of six different nucleoside analogs to induce cell death was then evaluated. Penciclovir (PCV) showed the most interesting properties with an efficiency comparable to ganciclovir (GCV), but low toxicity. We tested three nucleoside analogs in vivo: at concentrations of 40 mg/kg/day, PCV and GCV prevented tumor formation, while acyclovir (ACV) did not. In summary, SR39h under the control of a cell cycle-dependent promoter appears most efficient and selective as safety switch for neural transplants. In this setting, PCV and GCV are efficient inducers of cell death. Because of its low toxicity, PCV might become a preferred alternative to GCV.
Keywords	SR39 ; penciclovir ; pluripotent stem cell therapy ; teratoma ; post-transplantation tumor ; Biology (General) ; QH301-705.5
Language	English
Publishing date	2022-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: [No title information]

Berlincourt, Jade / Bury, Agnès / Farhat, Hania / Khadam-Al-Jame, Tasnim / Maag, Anja / Adomako, Benjamin K / Carnesecchi, Stéphanie / Perrin, Jackie

Revue medicale suisse

2021 Volume 17, Issue 729, Page(s) 504–505

Title translation	L-sérine : l’antisèche de la mémoire.
MeSH term(s)	Humans ; Memory ; Serine
Chemical Substances	Serine (452VLY9402)
Language	French
Publishing date	2021-03-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2177010-4
ISSN	1660-9379
ISSN	1660-9379
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5998: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [No title information]

Bindschaedler, Clément / Chammartin, Nylsa / Gosetto, Margaux / Khatibi, Khatiba / Nemeth, Anthony / Poncet, Clément / Volery, Maxime / Carnesecchi, Stéphanie / Perrin, Jackie

Revue medicale suisse

2020 Volume 16, Issue 717, Page(s) 2351–2352

Title translation	Os secours.
MeSH term(s)	Bone Neoplasms ; Bone and Bones ; Humans
Language	French
Publishing date	2020-12-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2177010-4
ISSN	1660-9379
ISSN	1660-9379
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5998: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: NOX enzymes: potential target for the treatment of acute lung injury.

Carnesecchi, Stéphanie / Pache, Jean-Claude / Barazzone-Argiroffo, Constance

Cellular and molecular life sciences : CMLS

2012 Volume 69, Issue 14, Page(s) 2373–2385

Abstract: Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), is characterized by acute inflammation, disruption of the alveolar-capillary barrier, and in the organizing stage by alveolar pneumocytes hyperplasia and ... ...

Abstract	Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), is characterized by acute inflammation, disruption of the alveolar-capillary barrier, and in the organizing stage by alveolar pneumocytes hyperplasia and extensive lung fibrosis. The cellular and molecular mechanisms leading to the development of ALI/ARDS are not completely understood, but there is evidence that reactive oxygen species (ROS) generated by inflammatory cells as well as epithelial and endothelial cells are responsible for inflammatory response, lung damage, and abnormal repair. Among all ROS-producing enzymes, the members of NADPH oxidases (NOXs), which are widely expressed in different lung cell types, have been shown to participate in cellular processes involved in the maintenance of lung integrity. It is not surprising that change in NOXs' expression and function is involved in the development of ALI/ARDS. In this context, the use of NOX inhibitors could be a possible therapeutic perspective in the management of this syndrome. In this article, we summarize the current knowledge concerning some cellular aspects of NOXs localization and function in the lungs, consider their contribution in the development of ALI/ARDS and discuss the place of NOX inhibitors as potential therapeutical target.
MeSH term(s)	Acute Lung Injury/enzymology ; Acute Lung Injury/pathology ; Acute Lung Injury/therapy ; Cytokines/metabolism ; Enzyme Inhibitors/therapeutic use ; Humans ; NADPH Oxidases/antagonists & inhibitors ; NADPH Oxidases/metabolism ; Protein Isoforms/antagonists & inhibitors ; Protein Isoforms/metabolism ; Respiratory Distress Syndrome/enzymology ; Respiratory Distress Syndrome/pathology ; Respiratory Distress Syndrome/therapy
Chemical Substances	Cytokines ; Enzyme Inhibitors ; Protein Isoforms ; NADPH Oxidases (EC 1.6.3.-)
Keywords	covid19
Language	English
Publishing date	2012-05-13
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	1358415-7
ISSN	1420-9071 ; 1420-682X
ISSN (online)	1420-9071
ISSN	1420-682X
DOI	10.1007/s00018-012-1013-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 195: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: NOX3-TARGETED THERAPIES FOR INNER EAR PATHOLOGIES.

Rousset, Francis / Carnesecchi, Stephanie / Senn, Pascal / Krause, Karl-Heinz

Current pharmaceutical design

2015 Volume 21, Issue 41, Page(s) 5977–5987

Abstract: Inner ear pathologies are associated with major morbidity and loss of life quality in affected patients. In many of these conditions, production of reactive oxygen-species (ROS) is thought to be a key pathological mechanism. While the sources of ROS are ... ...

Abstract	Inner ear pathologies are associated with major morbidity and loss of life quality in affected patients. In many of these conditions, production of reactive oxygen-species (ROS) is thought to be a key pathological mechanism. While the sources of ROS are complex (including for example mitochondria), there is increasing evidence that activation of NOX enzymes, in particular NOX3, plays a key role. NOX3 is a multi-subunit NADPH oxidase, functionally and structurally closely related to NOX1 and NOX2. In both the vestibular and the cochlear compartments of the inner ear, high levels of NOX3 mRNA are expressed. In NOX3 mutant mice, the vestibular function is perturbed due to a lack of otoconia, while only minor alterations of hearing have been documented. However, there is increasing evidence that activation of NOX3 through drugs, noise and probably also aging, leads to hearing loss. Thus, NOX3 is an interesting target to treat and prevent inner ear pathologies and a few first animal models based on drug - or molecular therapy have been reported. So far however, there are no specific NOX3 inhibitors with a documented penetration into the inner ear. Nevertheless, certain antioxidants and non-specific NOX inhibitors diminish hearing loss in animal models. Development of small molecules inhibitors or molecular strategies against NOX3 could improve specificity and efficiency of redox-targeted treatments. In this review, we will discuss arguments for the involvement of NOX3 in inner ear pathologies and therapeutic approaches to target NOX3 activity.
MeSH term(s)	Animals ; Humans ; Labyrinth Diseases/drug therapy ; Labyrinth Diseases/metabolism ; Labyrinth Diseases/pathology ; Membrane Proteins/antagonists & inhibitors ; Membrane Proteins/genetics ; Membrane Proteins/metabolism ; NADPH Oxidases/antagonists & inhibitors ; NADPH Oxidases/genetics ; NADPH Oxidases/metabolism ; Reactive Oxygen Species/antagonists & inhibitors ; Reactive Oxygen Species/metabolism ; Small Molecule Libraries/chemical synthesis ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology
Chemical Substances	Membrane Proteins ; Reactive Oxygen Species ; Small Molecule Libraries ; NADPH Oxidases (EC 1.6.3.-) ; Nox3 protein, human (EC 1.6.3.-) ; Nox3 protein, mouse (EC 1.6.3.-)
Language	English
Publishing date	2015-08-25
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1304236-1
ISSN	1873-4286 ; 1381-6128
ISSN (online)	1873-4286
ISSN	1381-6128
DOI	10.2174/1381612821666151029112421
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4714: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: NOX enzymes: potential target for the treatment of acute lung injury

Carnesecchi, Stéphanie / Pache, Jean-Claude / Barazzone-Argiroffo, Constance

Cellular and molecular life sciences. 2012 July, v. 69, no. 14

2012

Abstract	Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), is characterized by acute inflammation, disruption of the alveolar-capillary barrier, and in the organizing stage by alveolar pneumocytes hyperplasia and extensive lung fibrosis. The cellular and molecular mechanisms leading to the development of ALI/ARDS are not completely understood, but there is evidence that reactive oxygen species (ROS) generated by inflammatory cells as well as epithelial and endothelial cells are responsible for inflammatory response, lung damage, and abnormal repair. Among all ROS-producing enzymes, the members of NADPH oxidases (NOXs), which are widely expressed in different lung cell types, have been shown to participate in cellular processes involved in the maintenance of lung integrity. It is not surprising that change in NOXs’ expression and function is involved in the development of ALI/ARDS. In this context, the use of NOX inhibitors could be a possible therapeutic perspective in the management of this syndrome. In this article, we summarize the current knowledge concerning some cellular aspects of NOXs localization and function in the lungs, consider their contribution in the development of ALI/ARDS and discuss the place of NOX inhibitors as potential therapeutical target.
Keywords	NADP (coenzyme) ; endothelial cells ; enzymes ; fibrosis ; hyperplasia ; inflammation ; pneumocytes ; reactive oxygen species ; covid19
Language	English
Dates of publication	2012-07
Size	p. 2373-2385.
Publishing place	Springer-Verlag
Document type	Article
ZDB-ID	1358415-7
ISSN	1420-9071 ; 1420-682X
ISSN (online)	1420-9071
ISSN	1420-682X
DOI	10.1007/s00018-012-1013-6
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 4' 47/14: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Rimeporide as a ﬁrst- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.

Previtali, Stefano C / Gidaro, Teresa / Díaz-Manera, Jordi / Zambon, Alberto / Carnesecchi, Stephanie / Roux-Lombard, Pascale / Spitali, Pietro / Signorelli, Mirko / Szigyarto, Cristina Al-Khalili / Johansson, Camilla / Gray, Julian / Labolle, Delphine / Porte Thomé, Florence / Pitchforth, Jacqueline / Domingos, Joana / Muntoni, Francesco

Pharmacological research

2020 Volume 159, Page(s) 104999

Abstract: Rimeporide, a ﬁrst-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. ... ...

Abstract	Rimeporide, a ﬁrst-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. There is considerable overlap in the pathophysiological mechanisms in Congestive Heart Failure (CHF) and in cardiomyopathy in DMD, therefore NHE-1 inhibition could be a promising pharmacological approach to the cardiac dysfunctions observed in DMD. Extensive preclinical data was collected in various animal models including dystrophin-deficient (mdx) mice to characterise Rimeporide's anti-fibrotic and anti-inflammatory properties and there is evidence that NHE-1 inhibitors could play a significant role in modifying DMD cardiac and also skeletal pathologies, as the NHE-1 isoform is ubiquitous. We report here the first study with Rimeporide in DMD patients. This 4-week treatment, open label phase Ib, multiple oral ascending dose study, enrolled 20 ambulant boys with DMD (6-11 years), with outcomes including safety, pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers. Rimeporide was safe and well-tolerated at all doses. PK evaluations showed that Rimeporide was well absorbed orally reaching pharmacological concentrations from the lowest dose, with exposure increasing linearly with dose and with no evidence of accumulation upon repeated dosing. Exploratory PD biomarkers showed positive effect upon a 4-week treatment, supporting its therapeutic potential in patients with DMD, primarily as a cardioprotective treatment, and provide rationale for further efficacy studies.
MeSH term(s)	Administration, Oral ; Child ; Drug Administration Schedule ; Europe ; Humans ; Male ; Models, Biological ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/metabolism ; Muscle, Skeletal/physiopathology ; Muscular Dystrophy, Duchenne/diagnosis ; Muscular Dystrophy, Duchenne/drug therapy ; Muscular Dystrophy, Duchenne/metabolism ; Muscular Dystrophy, Duchenne/physiopathology ; Neuromuscular Agents/administration & dosage ; Neuromuscular Agents/adverse effects ; Neuromuscular Agents/pharmacokinetics ; Sodium-Hydrogen Exchanger 1/antagonists & inhibitors ; Sodium-Hydrogen Exchanger 1/metabolism ; Treatment Outcome
Chemical Substances	Neuromuscular Agents ; SLC9A1 protein, human ; Sodium-Hydrogen Exchanger 1
Language	English
Publishing date	2020-06-12
Publishing country	Netherlands
Document type	Clinical Trial, Phase I ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	1003347-6
ISSN	1096-1186 ; 0031-6989 ; 1043-6618
ISSN (online)	1096-1186
ISSN	0031-6989 ; 1043-6618
DOI	10.1016/j.phrs.2020.104999
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 721: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito